Neuroprotective effect of lurasidone via antagonist activities on histamine in a rat model of cranial nerve involvement

He,Baoming; Yu,Liang; Li,Suping; Xu,Fei; Yang,Lili; Ma,Shuai; Guo,Yi

doi:10.3892/mmr.2018.8595

Neuroprotective effect of lurasidone via antagonist activities on histamine in a rat model of cranial nerve involvement

Authors:
- Baoming He
- Liang Yu
- Suping Li
- Fei Xu
- Lili Yang
- Shuai Ma
- Yi Guo
View Affiliations

Affiliations: Department of Neurology, Sichuan Academy of Medical Sciences, Sichuan People's Hospital, Chengdu, Sichuan 610072, P.R. China
Published online on: February 13, 2018 https://doi.org/10.3892/mmr.2018.8595
Pages: 6002-6008

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cranial nerve involvement frequently involves neuron damage and often leads to psychiatric disorder caused by multiple inducements. Lurasidone is a novel antipsychotic agent approved for the treatment of cranial nerve involvement and a number of mental health conditions in several countries. In the present study, the neuroprotective effect of lurasidone by antagonist activities on histamine was investigated in a rat model of cranial nerve involvement. The antagonist activities of lurasidone on serotonin 5‑HT7, serotonin 5‑HT2A, serotonin 5‑HT1A and serotonin 5‑HT6 were analyzed, and the preclinical therapeutic effects of lurasidone were examined in a rat model of cranial nerve involvement. The safety, maximum tolerated dose (MTD) and preliminary antitumor activity of lurasidone were also assessed in the cranial nerve involvement model. The therapeutic dose of lurasidone was 0.32 mg once daily, administered continuously in 14‑day cycles. The results of the present study found that the preclinical prescriptions induced positive behavioral responses following treatment with lurasidone. The MTD was identified as a once daily administration of 0.32 mg lurasidone. Long‑term treatment with lurasidone for cranial nerve involvement was shown to improve the therapeutic effects and reduce anxiety in the experimental rats. In addition, treatment with lurasidone did not affect body weight. The expression of the language competence protein, Forkhead‑BOX P2, was increased, and the levels of neuroprotective SxIP motif and microtubule end‑binding protein were increased in the hippocampal cells of rats with cranial nerve involvement treated with lurasidone. Lurasidone therapy reinforced memory capability and decreased anxiety. Taken together, lurasidone treatment appeared to protect against language disturbances associated with negative and cognitive impairment in the rat model of cranial nerve involvement, providing a basis for its use in the clinical treatment of patients with cranial nerve involvement.

View Figures

View References

1	Sakakibara Y, Mori M, Kuwabara S, Katayama K, Hattori T, Koga M and Yuki N: Unilateral cranial and phrenic nerve involvement in axonal Guillain-Barré syndrome. Muscle Nerve. 25:297–299. 2002. View Article : Google Scholar : PubMed/NCBI
2	Sahin E, Yilmaz A, Ersöz G, Uğuz M and Kaya A: Multiple cranial nerve involvement caused by Brucella melitensis. South Med J. 102:855–857. 2009. View Article : Google Scholar : PubMed/NCBI
3	Suzuki T: A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: A narrative review and critical appraisal. Expert Opin Drug Deliv. 13:253–264. 2016. View Article : Google Scholar : PubMed/NCBI
4	Bortolato B, Miskowiak KW, Köhler CA, Vieta E and Carvalho AF: Cognitive dysfunction in bipolar disorder and schizophrenia: A systematic review of meta-analyses. Neuropsychiatr Dis Treat. 11:3111–3125. 2015.PubMed/NCBI
5	Ushio M, Iwasaki S, Sugasawa K and Murofushi T: Superficial siderosis causing retrolabyrinthine involvement in both cochlear and vestibular branches of the eighth cranial nerve. Acta Otolaryngol. 126:997–1000. 2006. View Article : Google Scholar : PubMed/NCBI
6	Bahi A, Schwed JS, Walter M, Stark H and Sadek B: Anxiolytic and antidepressant-like activities of the novel and potent non-imidazole histamine H₃ receptor antagonist ST-1283. Drug Des Devel Ther. 8:627–637. 2014.PubMed/NCBI
7	Borella L, Russell J, Rimele TJ, Grimes D, Failli A and Mir GN: Antisecretory and antiulcer activities of a potent new histamine H2-receptor antagonist with an intermediate duration of action. Arzneimittelforschung. 38:366–372. 1988.PubMed/NCBI
8	Kent JS, Bolbecker AR, O'Donnell BF and Hetrick WP: Eyeblink conditioning in schizophrenia: A critical review. Front Psychiatry. 6:1462015. View Article : Google Scholar : PubMed/NCBI
9	McEvoy J and Citrome L: Brexpiprazole for the treatment of schizophrenia: A review of this novel serotonin-dopamine activity modulator. Clin Schizophr Relat Psychoses. 9:177–186. 2016. View Article : Google Scholar : PubMed/NCBI
10	Naito Y, Yoshikawa T, Matsuyama K, Yagi N, Nakamura Y, Nishimura S, Kaneko T, Yoshida N and Kondo M: Effect of the histamine H2-receptor antagonist (+/−)-(E)-1-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-3′-[2-[[[5-methylamino)methyl-2-furyl]methyl]thio]ethyl]-2′-(methylsulfonyl)guanidine on acute gastric mucosal injury in rats and its free-radical scavenging activities. Arzneimittelforschung. 47:845–848. 1997.PubMed/NCBI
11	Ishikawa H, Ito H, Higaki M, Higaki M, Matsumoto Y, Kamimura T, Katsura Y, Tomishi T, Inoue Y, Takasugi H, et al: FR145715, a novel histamine H2 receptor antagonist, with specific anti-Helicobacter pylori activities. Eur J Pharmacol. 378:299–310. 1999. View Article : Google Scholar : PubMed/NCBI
12	Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, et al: Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 334:171–181. 2010. View Article : Google Scholar : PubMed/NCBI
13	Loebel A and Citrome L: Lurasidone: A novel antipsychotic agent for the treatment of schizophrenia and bipolar depression. BJPsych Bull. 39:237–241. 2015. View Article : Google Scholar : PubMed/NCBI
14	Citrome L: Lurasidone for schizophrenia: A review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 65:189–210. 2011. View Article : Google Scholar : PubMed/NCBI
15	Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J and Calabrese JR: Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: A randomized, double-blind, placebo-controlled study. Am J Psychiatry. 171:169–177. 2014. View Article : Google Scholar : PubMed/NCBI
16	Citrome L: Lurasidone in schizophrenia: New information about dosage and place in therapy. Adv Ther. 29:815–825. 2012. View Article : Google Scholar : PubMed/NCBI
17	Nunes PM, Wright AJ, Veltien A, van Asten JJ, Tack CJ, Jones JG and Heerschap A: Dietary lipids do not contribute to the higher hepatic triglyceride levels of fructose-compared to glucose-fed mice. FASEB J. 28:1988–1997. 2014. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Wai-Hoe L, Wing-Seng L, Ismail Z and Lay-Harn G: SDS-PAGE-Based quantitative assay for screening of kidney stone disease. Biol Proced Online. 11:145–160. 2009. View Article : Google Scholar : PubMed/NCBI
20	Dirani M, Nasreddine W, Abdulla F and Beydoun A: Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel. Epilepsy Behav Case Rep. 2:164–166. 2014. View Article : Google Scholar : PubMed/NCBI
21	Vaisburd S, Shemer Z, Yeheskel A, Giladi E and Gozes I: Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model. Sci Rep. 5:163002015. View Article : Google Scholar : PubMed/NCBI
22	Berezova IV, Shishkina GT, Kalinina TS and Dygalo NN: Behavior in the forced-swimming test and expression of BDNF and Bcl-xl genes in the rat brain. Zh Vyssh Nerv Deiat Im I P Pavlova. 61:332–339. 2011.(In Russian). PubMed/NCBI
23	Garcia-Calero E, Botella-Lopez A, Bahamonde O, Perez-Balaguer A and Martinez S: FoxP2 protein levels regulate cell morphology changes and migration patterns in the vertebrate developing telencephalon. Brain Struct Funct. 221:2905–2917. 2016. View Article : Google Scholar : PubMed/NCBI
24	Chebel S, Letaief L, Boughammoura-Bouatay A, Dachraoui F, Ouanes I, Ouanes-Besbes L, Abroug F and Frih-Ayed M: Multiple cranial nerve involvement: Consider the diagnosis of cephalic tetanus. A case report and review of the literature. Rev Neurol (Paris). 166:948–950. 2010.(In French).
25	Mabray MC, Glastonbury CM, Mamlouk MD, Punch GE, Solomon DA and Cha S: Direct cranial nerve involvement by gliomas: Case series and review of the literature. AJNR Am J Neuroradiol. 36:1349–1354. 2015. View Article : Google Scholar : PubMed/NCBI
26	Mijajlovic M, Mirkovic M, Mihailovic-Vucinic V, Aleksic V and Covickovic-Sternic N: Neurosarcoidosis: Two case reports with multiple cranial nerve involvement and review of the literature. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 158:662–667. 2014.PubMed/NCBI
27	Galassi G, Albertini G, Valzania F and Barbieri A: Cranial nerve involvement as presenting sign of multifocal motor neuropathy. J Clin Neurosci. 19:1733–1735. 2012. View Article : Google Scholar : PubMed/NCBI
28	Watanabe Y, Someya T and Nawa H: Cytokine hypothesis of schizophrenia pathogenesis: Evidence from human studies and animal models. Psychiatry Clin Neurosci. 64:217–230. 2010. View Article : Google Scholar : PubMed/NCBI
29	de Witte L, Tomasik J, Schwarz E, Guest PC, Rahmoune H, Kahn RS and Bahn S: Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment. Schizophr Res. 154:23–29. 2014. View Article : Google Scholar : PubMed/NCBI
30	Debnath M and Chaudhuri TK: The role of HLA-G in cytokine homeostasis during early pregnancy complicated with maternal infections: A novel etiopathological approach to the neurodevelopmental understanding of schizophrenia. Med Hypotheses. 66:286–293. 2006. View Article : Google Scholar : PubMed/NCBI
31	Bhattarai JP, Roa J, Herbison AE and Han SK: Serotonin acts through 5-HT1 and 5-HT2 receptors to exert biphasic actions on GnRH neuron excitability in the mouse. Endocrinology. 155:513–524. 2014. View Article : Google Scholar : PubMed/NCBI
32	Girgis RR, Kumar SS and Brown AS: The cytokine model of schizophrenia: Emerging therapeutic strategies. Biol Psychiatry. 75:292–299. 2014. View Article : Google Scholar : PubMed/NCBI
33	Andrade R and Haj-Dahmane S: Serotonin neuron diversity in the dorsal raphe. ACS Chem Neurosci. 4:22–25. 2013. View Article : Google Scholar : PubMed/NCBI
34	Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Oertel WH, Björklund A, Lindvall O and Piccini P: Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Sci Transl Med. 4:128ra412012. View Article : Google Scholar : PubMed/NCBI
35	Mlinar B, Montalbano A, Baccini G, Tatini F, Berlinguer Palmini R and Corradetti R: Nonexocytotic serotonin release tonically suppresses serotonergic neuron activity. J Gen Physiol. 145:225–251. 2015. View Article : Google Scholar : PubMed/NCBI